IgA Nephropathy Clinical Trials
2 recruiting trials for IgA Nephropathy. Eligibility criteria explained in plain English.
TrialFinderData lists 2 IgA Nephropathy clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 4 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by UK Kidney Association (1), Christian Medical College, Vellore, India (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Oral prednisolone and SoC (drug, 1 trial), followed by Gut-directed budesonide and SoC, Mycophenolate mofetil (MMF) and SoC.
Track IgA Nephropathy trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research. The purpose of this research...
Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope...
Global Burden of Diseases ranks chronic kidney disease (CKD) as the 12th leading cause of death, with an estimated 20% increase from 2010 to 2019. India is the most populous...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for IgA Nephropathy, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for IgA Nephropathy, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for IgA Nephropathy, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.